- Conditions
- Sickle Cell Disease
- Interventions
- Etavopivat, Placebo
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 510 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 49
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 37 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 265–288
of 2,062
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Iron-deficiency, Iron Deficiency Anaemia Due to Dietary Causes, Iron Deficiency Anemia Treatment, Iron Deficiency Anemia
- Interventions
- Ferrous sulfate, Ferrous sulfate-enriched Aspergillus oryzae (Ao iron)
- Dietary Supplement
- Lead sponsor
- Iowa State University
- Other
- Eligibility
- 18 Years to 44 Years · Female only
- Enrollment
- 15 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Ames, Iowa
- Conditions
- Anemia, Leukemia, Neutropenia, Thrombocytopenia
- Interventions
- filgrastim, leridistim, cytarabine, daunorubicin hydrochloride
- Biological · Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 55 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2000
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Sickle Cell Disease, Hemoglobinopathies
- Interventions
- EDIT-301
- Genetic
- Lead sponsor
- Editas Medicine, Inc.
- Industry
- Eligibility
- 12 Years to 50 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 21
- States / cities
- Oakland, California • Aurora, Colorado • New Haven, Connecticut + 15 more
- Conditions
- Hematologic Disease and Disorders, Donors, Healthy Volunteer
- Interventions
- Not listed
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 2 Years to 100 Years
- Enrollment
- 10,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 1996
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Sickle Cell Disease
- Interventions
- Red Blood Cell, Standard of care
- Biological · Other
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 173 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 20
- States / cities
- Tuscaloosa, Alabama • Oakland, California • Washington D.C., District of Columbia + 15 more
- Conditions
- Sickle Cell Disease
- Interventions
- Osivelotor
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 389 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2032
- U.S. locations
- 46
- States / cities
- Mobile, Alabama • Hartford, Connecticut • New Haven, Connecticut + 27 more
- Conditions
- Sickle Cell Anemia
- Interventions
- Prasugrel, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 14
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Sacramento, California + 11 more
- Conditions
- Sickle Cell Disease
- Interventions
- mobile health application
- Other
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 2
- States / cities
- Columbus, Ohio • Nashville, Tennessee
- Conditions
- Iron-deficiency Anemia
- Interventions
- Clinical supports
- Behavioral
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 2
- States / cities
- Chicago, Illinois
- Conditions
- Breast Cancer, Ovarian Cancer
- Interventions
- Culturally Tailored Genetic Counseling
- Behavioral
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years to 85 Years · Female only
- Enrollment
- 204 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2003 – 2012
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Myelodysplasia, Myeloproliferative Disorder, Myelofibrosis, Lymphoma, Lymphoma, Non-Hodgkin, Plasma Cell Disorder
- Interventions
- Cyclophosphamide, Fludarabine, Total Body Irradiation, Tacrolimus, cellcept, g-csf, Peripheral Blood Transplant
- Drug · Radiation · Procedure
- Lead sponsor
- Dartmouth-Hitchcock Medical Center
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2025
- U.S. locations
- 1
- States / cities
- Lebanon, New Hampshire
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Aplastic Anemia, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Myelomonocytic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Lymphoblastic Lymphoma, Myelodysplastic Syndrome, Myeloproliferative Neoplasm, Plasma Cell Myeloma, Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Recurrent Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Plasma Cell Myeloma, Therapy-Related Myelodysplastic Syndrome
- Interventions
- Cyclophosphamide, Filgrastim, Fludarabine Phosphate, Laboratory Biomarker Analysis, Melphalan, Peripheral Blood Stem Cell Transplantation, Rituximab, Tacrolimus, Total-Body Irradiation
- Drug · Biological · Other + 2 more
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Anemia, Cardiovascular Disease
- Interventions
- EPO, Feraheme
- Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 2
- States / cities
- Dallas, Texas
- Conditions
- Pyruvate Kinase Deficiency, Anemia, Hemolytic
- Interventions
- Placebo, AG-348
- Drug
- Lead sponsor
- Agios Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 12
- States / cities
- Little Rock, Arkansas • Atlanta, Georgia • Indianapolis, Indiana + 8 more
- Conditions
- Sickle Cell Disease
- Interventions
- Mitapivat, Mitapivat-matching placebo
- Drug · Other
- Lead sponsor
- Agios Pharmaceuticals, Inc.
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 286 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2030
- U.S. locations
- 28
- States / cities
- La Jolla, California • Los Angeles, California • Oakland, California + 20 more
- Conditions
- Sickle Cell Disease, Sickle-Beta Zero Thalassemia
- Interventions
- SCD-101
- Drug
- Lead sponsor
- Invenux, LLC
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2023
- U.S. locations
- 1
- States / cities
- Brooklyn, New York
- Conditions
- Anemia, Renal Insufficiency, Chronic, Renal Anemia
- Interventions
- Daprodustat
- Drug
- Lead sponsor
- USRC Kidney Research
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 161 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Lone Tree, Colorado
- Conditions
- Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Biphenotypic/Undifferentiated Leukemia, Chronic Myelogenous Leukemia, Myelodysplasia, Relapsed Large Cell Lymphoma, Mantle Cell Lymphoma, Hodgkin Lymphoma, Burkitt Lymphoma, Relapsed T-Cell Lymphoma, Lymphoplasmacytic Lymphoma
- Interventions
- Fludarabine (FLU), Cyclophosphamide (CY), Total Body Irradiation (TBI), Tacrolimus (Tac), Mycophenolate Mofetil (MMF), Granulocyte Colony-Stimulating Factor (G-CSF), Busulfan (BU), Melphalan, MGTA 456 Infusion
- Drug
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- Up to 55 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Sickle Cell Disease (SCD), Vaso-Occlusive Pain Episode in Sickle Cell Disease
- Interventions
- Depot medroxyprogesterone acetate (DMPA)
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia • Philadelphia, Pennsylvania
- Conditions
- Pyruvate Kinase Deficiency, Anemia, Hemolytic
- Interventions
- AG-348
- Drug
- Lead sponsor
- Agios Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 4
- States / cities
- Oakland, California • Atlanta, Georgia • Boston, Massachusetts + 1 more
- Conditions
- Paroxysmal Nocturnal Hemoglobinuria (PNH)
- Interventions
- ALXN1102, ALXN1103
- Drug
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Sickle Cell Disease
- Interventions
- Not listed
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Chronic Myeloid Leukemia, Acute Myelogenous Leukemia, Myelodysplasia, Acute Lymphocytic Leukemia, Severe Aplastic Anemia, Non-Hodgkin's Lymphoma, Lymphoproliferative Disease, Multiple Myeloma, Advanced Myeloproliferative Disease
- Interventions
- Busulfan/Fludarabine phosphate/Tacrolimus/Methotrexate/G-CSF
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 15 Years to 61 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2007
- U.S. locations
- 1
- States / cities
- San Francisco, California